Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma

Figure 1 A flow chart of the experimental design. HCC: Hepatocellular carcinoma; ROC: Receiver-operating-characteristic curve.

Figure 2 Relative contents of the selected four miRNAs in the sera from patient with hepatocellular carcinoma in the validation phase. The asterisks indicate significant differences from normal controls (P < 0.05). ^eP < 0.001. NC: Normal controls; HCC: Hepatocellular carcinoma.

Figure 3 Sensitivity and specificity of the four-miRNA and their panel in the validation phase set. HCC: Hepatocellular carcinoma; ROC: Receiver-operating-characteristic curve; AUC: Area under the ROC curve.

Figure 4 Relative contents of the four serum miRNAs in sera from hepatocellular carcinoma patients before and after surgery. A-D: The contents of four miRNAs including miR-10a, miR-122, miR-375 and miR-423 in paired serum samples of 80 HCC patients before and 7-10 d after an operation were assayed by RT-qPCR assay. The relative levels of miRNAs were normalized to let-7-d/g/i and calculated using the 2^-ΔΔCq method.